Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 2Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 13Lymphoid 12Other hematologic neoplasm 10CNS 6Gynecologic 2Genitourinary 2Sarcoma 1Other solid neoplasm 1NET 1Gastrointestinal 1Endocrine 1Dermatologic 1Breast 1

Conditions

Neuroendocrine Tumors 18Pituitary Neoplasms 5Pheochromocytoma 3Insulinoma 3Thyroid Carcinoma, Anaplastic 2Pituitary ACTH Hypersecretion 2Paraganglioma 2Neuroblastoma 2Multiple Endocrine Neoplasia Type 1 2Meningioma 2Lung Neoplasms 2Kidney Neoplasms 2Carcinoma, Renal Cell 2Carcinoid Tumor 2Breast Neoplasms 2Adrenocortical Carcinoma 2Adrenal Gland Neoplasms 2von Hippel-Lindau Disease 1Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Thyroid cancer, medullary 1Thyroid Cancer, Papillary 1Sexual Infantilism 1Serotonin Syndrome 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroma, Acoustic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Recurrence × Endocrine × Clear all
NCT06148636 2025-11-04

A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors

University of Iowa

Phase EARLY_PHASE1 Active not recruiting
24 enrolled
EndocrineNET

Adenoma, Islet Cell, Recurrence, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡